Evidence map›Paper›PMID 33008914›Full record

ArticleScience immunology2020

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

James C Lee, Sadaf Mehdizadeh, Jennifer Smith, Arabella Young, Ilgiz A Mufazalov, Cody T Mowery, Adil Daud, Jeffrey A Bluestone

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 216 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
216citing papers in PubMed, 5 pooled it
12.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

216 citing papers in PubMed, 5 syntheses or guidelines pooled it, 284 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  18. Review
  19. Article
  20. Article

156 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

James C LeeDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA. jeff.bluestone@ucsf.edu james.lee4@ucsf.edu.ORCID 0000-0002-1762-1677
Sadaf MehdizadehSean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-2489-1122
Jennifer SmithSean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-5662-1776
Arabella YoungSean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-6845-9753
Ilgiz A MufazalovSean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-9332-0131
Cody T MoweryDiabetes Center, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0003-2939-013X
Adil DaudDivision of Hematology and Oncology, University of California, San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0002-6617-8421
Jeffrey A BluestoneSean N. Parker Autoimmune Research Laboratory, University of California, San Francisco, San Francisco, CA 94143, USA. jeff.bluestone@ucsf.edu james.lee4@ucsf.edu.ORCID 0000-0001-8793-7848
University of California, San Francisco · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
NCI NIH HHS L30 CA254900NIAID NIH HHS L30 AI134628NIAID NIH HHS T32 AI007334NIGMS NIH HHS T32 GM007618
6 · The paper itself

Abstract

Patients with cancer with liver metastasis demonstrate significantly worse outcomes than those without liver metastasis when treated with anti-PD-1 immunotherapy. The mechanism of liver metastases-induced reduction in systemic antitumor immunity is unclear. Using a dual-tumor immunocompetent mouse model, we found that the immune response to tumor antigen presence within the liver led to the systemic suppression of antitumor immunity. The immune suppression was antigen specific and associated with the coordinated activation of regulatory T cells (T

Indexed as

AnimalsAntineoplastic Combined Chemotherapy ProtocolsCD11b AntigenCD8-Positive T-LymphocytesCell Line, TumorCTLA-4 AntigenDisease Models, AnimalDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinFemaleHumansImmune Checkpoint InhibitorsLiver NeoplasmsLymphocyte DepletionLymphocytes, Tumor-InfiltratingMaleCD11b AntigenCTLA-4 AntigenCtla4 protein, mouseEnhancer of Zeste Homolog 2 ProteinEzh2 protein, mouseImmune Checkpoint InhibitorsItgam protein, mouse

Identifiers

PMID33008914
PMCPMC7755924
OpenAlexW3089784677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.